Forging the future of pain relief
Creators of next generation treatments for inflammation and pain
Creators of next generation treatments for inflammation and pain
The only company developing disruptive treatments for detrimental inflammation and pain by harnessing the natural power of maresin compounds. Our innovative approach leverages the unique properties of these advanced anti-inflammatory compounds to stimulate the body’s natural resolution of inflammation while simultaneously blocking pain signaling.
Our unique compounds, licensed from Harvard University, clinical expertise, and synergistic drug development programs position us as the partner of choice for companies seeking to elevate their portfolios with truly unique formulations. Together with our leading market experience, we can pioneer a new frontier of life-changing therapeutics that stop chronic inflammation at its source.
Maresins are naturally occurring lipids that form part of the group of Specialized Pro-resolving Mediators (SPMs). Recent breakthrough science reveals that SPMs, including maresins, are critical components of the inflammation resolution machinery.
Inflammation is a physiological response necessary to protect the body from infections and injuries. However, if this inflammation is not properly resolved it can have a detrimental effect on health - causing pain and potentially leading to the development of chronic disease. Stopping the root cause of inflammation is key to solving this problem. That’s where maresins come in.
Demonstrating powerful anti-inflammatory and analgesic properties, maresins can relieve pain while promoting tissue health and recovery to support disease resolution – at its source.1 This opens doors of opportunity to expand treatment options for patients suffering from diseases caused or amplified by uncontrolled inflammation, such as vulvodynia, cancer, autoimmune diseases and neurological diseases.
Targets inflammation
Maresin 1 (MaR1) acts on the root cause of inflammation by stimulating the body’s natural resolution process
Blocks pain
MaR1 blocks peripheral and central pain signaling pathways7
Powerful pain relievers
SPMs act as more powerful pain relievers than opioids8
Fewer negative side effects
MaR1 is non-immunosuppressive and non-addictive8
Superior safety profile
MaR1 have a superior safety profile compared to traditional anti-inflammatories
In various animal models, maresins have shown to have a powerful, and safe potent, positive impact on inflammation and pain associated with several conditions, including vulvodynia. There is currently no approved medication on the market for vulvodynia. Maresins Biopharma is preparing a clinical trial with its topical formulation containing MaR1 pro-drug for testing it in vulvodynia patients.
Maresins compounds have also shown promising potential in treating lupus, as well as skin-related diseases, such as vitiligo, psoriasis and atopic dermatitis. Maresins Biopharam has drug development programs for these indications too. They have also shown promising potential in treating vulvodynia, which currently has no approved medication on the market. Clinical demonstration for vulvodynia is on its way.
